PARIS — Two studies presented here show that the CoreValve transcatheter aortic valve replacement system results in low mortality and stroke rates at 1 year and is cost effective in patients at high surgical risk.
Both studies featured data from the ADVANCE trial, which looked at “real-world” outcomes of the CoreValve TAVR system (Medtronic) in 1,015 patients from 44 centers in 12 countries in Western Europe, Asia and South America. The TAVR device was implanted in 996 patients with severe aortic stenosis who were deemed high risk for surgery.
More »